NASDAQ:PHAT Phathom Pharmaceuticals Q1 2025 Earnings Report $4.11 -0.01 (-0.24%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$4.12 +0.01 (+0.24%) As of 04/25/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Phathom Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$1.06Beat/MissN/AOne Year Ago EPSN/APhathom Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$27.91 millionBeat/MissN/AYoY Revenue GrowthN/APhathom Pharmaceuticals Announcement DetailsQuarterQ1 2025Date5/1/2025TimeBefore Market OpensConference Call DateThursday, May 1, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Phathom Pharmaceuticals Earnings HeadlinesPhathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025April 23, 2025 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Earns "Buy" Rating from Needham & Company LLCApril 22, 2025 | americanbankingnews.comCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…April 28, 2025 | Investors Alley (Ad)Phathom Pharmaceuticals (NASDAQ:PHAT) shareholders have endured a 87% loss from investing in the stock five years agoApril 18, 2025 | finance.yahoo.comPhathom Pharmaceuticals appoints Schroeder to board of directorsApril 16, 2025 | markets.businessinsider.comPhathom Pharmaceuticals Appoints Ted Schroeder to its Board of DirectorsApril 16, 2025 | globenewswire.comSee More Phathom Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Phathom Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phathom Pharmaceuticals and other key companies, straight to your email. Email Address About Phathom PharmaceuticalsPhathom Pharmaceuticals (NASDAQ:PHAT), biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.View Phathom Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Upcoming Earnings AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025)Booking (4/29/2025)América Móvil (4/29/2025)Pfizer (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
